MPO and neoplasm: The marked reduction in tumor ROS observed in both MPO−/− and PAD4−/− mice, as well as following pharmacologic NET inhibition with HCQ, support the interpretation that neutrophils, and specifically NET-associated pathways, are major contributors to the elevated ROS detected in PDAC tumors.